As of Oct 02
| +0.59 / +2.15%|
The 7 analysts offering 12-month price forecasts for Acorda Therapeutics Inc have a median target of 42.00, with a high estimate of 65.00 and a low estimate of 32.00. The median estimate represents a +49.73% increase from the last price of 28.05.
The current consensus among 9 polled investment analysts is to Hold stock in Acorda Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.